Last reviewed · How we verify
NCT07380867: Tattooing
Confirming the Accuracy of Endoscopic Marking Using a New Marker, a Novel Luminomarker, in Lesion Marking Before Colorectal Cancer Surgery.
NA trial testing LuminoMark inj. 0.2mL in Colorectal Cancer in 30 participants. Enrolling by invitation.
31 December 2026
Quick facts
| Lead sponsor | Seoul St. Mary's Hospital |
|---|---|
| Phase | NA |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 30 |
| Start date | 22 December 2025 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- LuminoMark inj. 0.2mL — full drug profile →
Conditions studied
- Colorectal Cancer — all drugs for Colorectal Cancer →
- Endoscopic Tattoo of Suspected Colon Cancer — all drugs for Endoscopic Tattoo of Suspected Colon Cancer →
- Indocyanine Green (ICG) — all drugs for Indocyanine Green (ICG) →
Sponsor
Seoul St. Mary's Hospital
Who can join
Adults 19 to 80, any sex, with Colorectal Cancer or Endoscopic Tattoo of Suspected Colon Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Early-stage lesions are difficult to identify intraoperatively during colorectal cancer surgery. Therefore, preoperative lesion marking using a colonoscopic approach is crucial to confirm the location and extent of resection during surgery. Preoperative lesion location can help determine the optimal extent of resection, thereby increasing the accuracy of colorectal surgery. This is particularly true for cases requiring surgery after early-stage colorectal cancer or endoscopic tumor resection. Therefore, preoperative marking with indocyanine green (IDG) allows for laparoscopic identification of the lesion. This is crucial because it allows for precise lesion location, thereby enhancing surgical accuracy and preventing the need for unnecessary additional resections.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07380867
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of LuminoMark inj. 0.2mL
Trials testing the same drug.
- NCT03743259 — To Evaluate the Efficacy and Safety of LuminoMark Injection in Patients With Nonpalpable Breast Lesions · Phase 2 · completed
Other recruiting trials for Colorectal Cancer
Currently open trials in the same condition.
- NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
- NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting
Other Seoul St. Mary's Hospital trials
Trials by the same sponsor.
- NCT07345026 — Acellular Dermal Matrix(SureDerm BCS) in Breast-Conserving Surgery for Breast Cancer Patients · NA · not yet recruiting
- NCT07240844 — Enavogliflozin for the Management of Patients With Amyloid CardiomyopaThy · Phase 4 · not yet recruiting
- NCT06769087 — Comparing Immediate Removal and Postoperative 1 Day of Urinary Catheter After Colorectal Cancer Surgery · NA · enrolling by invitation
- NCT06442111 — The Role of Intravenous Ferritin in Optimizing Postoperative Recovery Following Pancreaticoduodenectomy · NA · not yet recruiting
- NCT06202885 — CAREMM-2306: Advanced Immunotherapy vs. Classical Immunotherapy · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07380867 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Seoul St. Mary's Hospital
- Last refreshed: 2 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07380867.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing